Diligence memo · auto-generated · as of July 2, 2026

Three Rivers Pharmaceuticals Llc

Three Rivers Pharmaceuticals Llc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Three Rivers Pharmaceuticals Llc operates in Pharmaceuticals, based in WARRENDALE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Three Rivers Pharmaceuticals Llc has raised $6.6M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $6.6M on 2009-02-16.

Most recent recorded round closed around 2009-02-16.

Valuation (modeled)modeled

Provath models Three Rivers Pharmaceuticals Llc at approximately $203M (range $7.5M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.74× the median modeled value of Series A Pharmaceuticals companies in 2007–2009 (18 peers) — value vs value, same stage and era. Within the normal band (74% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 17.4 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 47% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 69% of those peers.

Closest niche peers: Sinocom Pharmaceutical, Inc., Vitae Pharmaceuticals, Inc, QUATRX PHARMACEUTICALS Co, Qrxpharma Ltd, Elixir Pharmaceuticals, Inc..

Peoplefiled

6 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.